STAT+: Allogenes off-the-shelf CAR-T is nearing an...
A preliminary readout from a study could vindicate Allogene Therapeutics' stubborn belief in its off-the-shelf CAR-T treatment.
What’s Happening
Let’s talk about A preliminary readout from a study could vindicate Allogene Therapeutics’ stubborn belief in its off-the-shelf CAR-T treatment.
Adams Biotech Scorecard Adams Biotech Scorecard STAT Plus: Six drugmakers, six months: Charting the FDA’s course in the post-Prasad era By Adam Feuerstein Adams Biotech Scorecard Adams Biotech Scorecard STAT Plus: The extremism of the FDAs Marks and Prasad has come with costs By Adam Feuerstein Adams Biotech Scorecard Adams Biotech Scorecard STAT Plus: Xenons seizure drug study reads out soon. (let that sink in)
Heres what to expect By Adam Feuerstein Adams Biotech Scorecard Adams Biotech Scorecard STAT Plus: What to expect from Gossamer Bios late-stage lung disease study By Adam Feuerstein Adams Biotech Scorecard Adams Biotech Scorecard STAT Plus: The old Vinay Prasad never left.
Why This Matters
This is the kind of health news that affects everyday decisions.
Health experts are weighing in on what this means for people.
The Bottom Line
This story is still developing, and we’ll keep you updated as more info drops.
What’s your take on this whole situation?
Daily briefing
Get the next useful briefing
If this story was worth your time, the next one should be too. Get the daily briefing in one clean email.
Reader reaction
